Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celon Pharma's dividends per share for the
three
months ended in Mar. 2026 was zł0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.00. Its Dividend Payout Ratio for the
three
months ended in Mar. 2026 was 0.00. As of today, Celon Pharma's Dividend Yield % is 0.00%.
During the past 12 months, Celon Pharma's average Dividends Per Share Growth Rate was -100.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 11 years, the highest 3-Year average Dividends Per Share Growth Rate of Celon Pharma was 4.60% per year. The lowest was -25.60% per year. And the median was -9.10% per year.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Celon Pharma (WAR:CLN) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Celon Pharma's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as
During the past 11 years, the highest Dividend Payout Ratio of Celon Pharma was 0.93. The lowest was 0.26. And the median was 0.30.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
During the past 11 years, the highest Dividend Yield of Celon Pharma was 0.85%. The lowest was 0.00%. And the median was 0.48%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma Dividends per Share Related Terms
Celon Pharma Dividends per Share Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: Dividends per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Dividend Yield % falls into.
Celon Pharma (WAR:CLN) has a Dividends per Share of zł0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Dividends per Share too high?
Celon Pharma's current Dividends per Share is zł0.00. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Dividends per Share compare to ZTS and UTHR?
Celon Pharma's Dividends per Share of zł0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Celon Pharma and its competitors. Celon Pharma's current Dividends per Share is zł0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.66, compared to a current price of zł21.00 — trading 11.2% below its estimated fair value. The current Dividends per Share is zł0.00. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Dividends per Share is zł0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł21.00 is trading 11.2% below its estimated GF Value™ of zł23.66.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
Dividends per Share: zł0.00
GF Value™: zł23.66 vs. price of zł21.00 (11.2% below fair value)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score
Get the complete analysis for WAR:CLN
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
